ReviewNeuro-oncology2022
Surveillance imaging frequency in adult patients with lower-grade (WHO Grade 2 and 3) gliomas.
Review in Neuro-oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- SEOM-GEINO clinical guidelines for grade 2 gliomas (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Multidisciplinary recommendations for routine follow-up of isocitrate dehydrogenase‑mutant glioma in 2026: Adapting clinical practice to the molecular era.Neuro-oncology practice · 2026Review
- Malignant transformation of lower-grade glioma: contrast enhancement, extent of resection, and the natural history under interval-censored analysis.Journal of neuro-oncology · 2026Article
- Management of Adult Patients With Isocitrate Dehydrogenase-Mutant Gliomas in Australia: An Expert Position Statement From the Cooperative Trials Group for Neuro-Oncology.Asia-Pacific journal of clinical oncology · 2026Review
- Isocitrate Dehydrogenase-Mutant Astrocytomas: Risk Stratification and Therapeutic Advance.MedComm · 2026Review
- Integrating Single-Cell and RNA Sequencing to Predict Glioma Prognosis Through Lactylation.International journal of molecular sciences · 2026Article
- Development and validation of radiopathomics models for predicting molecular subtypes and WHO grades in adult-type diffuse gliomas: a multicenter study.Journal of translational medicine · 2025Article
- RANO 2.0: critical updates and practical considerations for radiological assessment in neuro-oncology.Japanese journal of radiology · 2025Review
- Deep learning-based quantification of T2-FLAIR mismatch sign: extending IDH mutation prediction in adult-type diffuse lower-grade glioma.European radiology · 2025Article
- Advanced MRI, Radiomics and Radiogenomics in Unravelling Incidental Glioma Grading and Genetic Status: Where Are We?Medicina (Kaunas, Lithuania) · 2025Review
- Characteristics and Outcomes of Patients With IDH-Mutant Grade 2 and 3 Gliomas After Deferred or Adjuvant Radiotherapy.Neurology · 2025Observational
- Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomas.Discover oncology · 2025Review
- Article
- Contemporary Patterns of Care for Low-Grade Glioma in Australia and New Zealand.Current oncology (Toronto, Ont.) · 2025Article
- Precision radiotherapy with molecular-profiling of CNS tumours.Journal of neuro-oncology · 2025Review
- Treatment Options for IDH-Mutant Malignant Gliomas.Current treatment options in oncology · 2024Review
- Significant Genes Associated with Mortality and Disease Progression in Grade II and III Glioma.Biomedicines · 2024Article
- Altering patterns of sensorimotor network in patients with different pathological diagnoses and glioma-related epilepsy under the latest glioma classification of the central nervous system.CNS neuroscience & therapeutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With improved outcome following aggressive treatment in patients with grade 2 and 3 IDH-mutant (IDHmt), 1p/19q codeleted oligodendroglioma and IDHmt, non-codeleted astrocytoma, prolonged surveillance is desirable for early detection of tumor growth and malignant transformation. Current National Comprehensive Cancer Network (NCCN) guidelines provide imaging follow-up recommendations based on molecular classification of lower-grade gliomas, although individualized imaging guidelines based on treatments received and after tumor recurrence are not clearly specified. Other available guidelines have yet to incorporate the molecular biomarkers that inform the WHO classification of gliomas, and in some cases do not adequately consider current knowledge on IDHmt glioma growth rate and recurrence patterns. Moreover, these guidelines also do not provide specific recommendations for concerning clinical symptoms or radiographic findings warranting imaging studies out of prespecified intervals. Focusing on molecularly defined grade 2 and 3 IDHmt astrocytomas and oligodendrogliomas, we review current knowledge of tumor growth rates and time to tumor progression for each tumor type and propose a range of recommended MRI surveillance intervals for both the newly diagnosed and recurrent tumor setting. Additionally, we summarize situations in which imaging is advisable outside of these intervals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.